Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activityResearch in context

Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activityResearch in context

Summary: Background: HexaBody®-CD38 (GEN3014) is a hexamerization-enhanced human IgG1 that binds CD38 with high affinity. The E430G mutation in its Fc domain facilitates the natural process of antibody hexamer formation upon binding to the cell surface, resulting in increased binding of C1q and pot...

Full description

Bibliographic Details
Main Authors: Ida H. Hiemstra, Kim C.M. Santegoets, Maarten L. Janmaat, Bart E.C.G. De Goeij, Wessel Ten Hagen, Sanne van Dooremalen, Peter Boross, Jeroen van den Brakel, Sieto Bosgra, Grietje Andringa, Berris van Kessel-Welmers, Dennis Verzijl, Richard G. Hibbert, Kristine A. Frerichs, Tuna Mutis, Niels W.C.J. van de Donk, Tahamtan Ahmadi, David Satijn, A. Kate Sasser, Esther C.W. Breij
Format: Article
Language:English
Published: Elsevier 2023-07-01
Series:EBioMedicine
Subjects:
Antibody
CD38
Complement-dependent cytotoxicity
Hematologic neoplasms
Daratumumab
Multiple myeloma
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396423002281

Internet

http://www.sciencedirect.com/science/article/pii/S2352396423002281

Similar Items